Study title: A 12-week randomized, multicenter, double-blind, double-dummy, placebo and active controlled, parallel group study evaluating the safety and efficacy of Formoterol fumarate (10 µg b.i.d.) delivered by the multi-dose dry powder inhaler (MDDPI) versus place
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Respiratory Tract Diseases | |||||
Brands: | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: FORMOTEROL | |||||
ATC code: R03A C13 | |||||
Document link: FOR258F2302 Art45 listing 2011.xls | |||||
Document date: 2011-11-22 | |||||
Study number: CFOR258F2302 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |